Chemoradiotherapy Improves OS in Anaplastic Oligodendroglioma

Share this content:
(ChemotherapyAdvisor) – Procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) “may be an especially effective treatment” for a subset of patients with 1p/19q co-deleted anaplastic oligodendrogliomas, both pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), long-term results of a study in the Journal of Clinical Oncology online October 15 has found.

Previously, studies have shown that patients with AO and AOA, which have a common molecular ancestry, are chemosensitive. However, to determine whether chemoradiotherapy can improve overall survival (OS), the Radiation Therapy Oncology Group (RTOG) 9402 phase 3 study randomly assigned 291 eligible patients with AO/AOA to PCV plus RT (n=148) or RT alone (n=143), reported lead author J. Gregory Cairncross, MD, of Foothills Medical Centre, Calgary, Alberta, Canada.

The investigators found no difference in median survival by treatment for the entire cohort; 4.6 years for PCV plus RT vs 4.7 years for RT (HR 0.79; 95% CI, 0.60 to 1.04; P=0.1).

However, they observed “patients with co-deleted tumors lived longer than those with non−co-deleted tumors”: in the PCV plus RT arm, median OS was 14.7 years vs 2.6 years (HR 0.36; 95% CI, 0.23−0.57; P<0.001) and, in the RT alone arm, 7.3 vs 2.7 years (HR 0.40, 95% CI, 0.27−0.60, P<0.001). Median OS of those with co-deleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 vs 7.3 years; HR 0.59; 95% CI, 0.37−0.95; P=0.03),” Dr. Cairncross reported.

Among patients with non−co-deleted tumors, no difference in median OS by treatment arm was observed, 2.6 vs 2.7 years (HR 0.85; 95% CI, 0.58−1.23; P=0.39). In an unplanned analysis, the adjusted OS for all patients was prolonged by PCV plus RT (HR 0.67; 95% CI, 0.50−0.91; P=0.01).

An accompanying editorial noted, “These results have several important implications…[and] establish a new standard of care for patients with AO tumors that harbor the 1p/19q loss. No longer is radiation considered an adequate treatment for this patient population.”Based on these results, an international cooperative group study of newly diagnosed AO with 1p/19q loss (CODEL) was halted because the control arm, radiation alone, is no longer viable.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs